Algeta advances its radiopharmaceutical

Friday 13 August 2010

Algeta ASA is increasing manufacturing capacity for its lead product, a radiopharmaceutical, as recruitment continues in a pivotal Phase 3 trial of the product in patients with bone metastases arising from hormone-refractory prostate cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Norway